5-HT1A receptors are involved in the anxiolytic effect of Δ9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats

European Journal of Pharmacology

Volumn 555, Issue 2-3, 2007, Pages 156-163

  Braida, Daniela ^a   Limonta, Valeria ^a   Malabarba, Lorenzo ^a   Zani, Alessia ^a   Sala, Mariaelvina ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anxiety; Emotional like behavior; Endocannabinoid; Serotonergic

Indexed keywords

2 DIBUTYLAMINO 8 HYDROXYTETRALIN; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; DRONABINOL; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROTRANSMITTER; RECEPTOR SUBTYPE; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; AMIDE; ARACHIDONIC ACID DERIVATIVE; N (4 HYDROXYPHENYL)ARACHIDONYLAMIDE; N-(4-HYDROXYPHENYL)ARACHIDONYLAMIDE; PIPERAZINE DERIVATIVE; PSYCHOTROPIC AGENT; PYRIDINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; MALE; MAZE TEST; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; EXPLORATORY BEHAVIOR; METABOLISM; SPRAGUE DAWLEY RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANXIETY; ARACHIDONIC ACIDS; EXPLORATORY BEHAVIOR; MALE; PIPERAZINES; POLYUNSATURATED ALKAMIDES; PSYCHOTROPIC DRUGS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TETRAHYDROCANNABINOL;

EID: 33846014230     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.10.038     Document Type: Article

References (59)

1. Beltramo M., and Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 11 (2000) 1231-1235
2. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097
3. Beltramo M., Rodriguez de Fonseca F.R., Navarro M., Malignano A., Gorriti M.A., Grammatikopoulos G., Sadile A.G., Giuffrida A., and Piomelli D. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J. Neurosci. 20 (2000) 3401-3407
4. 9-tetrahydrocannabinol. Psychopharmacology 163 (2002) 111-117
5. 1A serotonin receptor potentiation by the biologically active lipid oleamide. Proc. Natl. Acad. Sci. 95 (1998) 4102-4107
6. Bortolato M.M., Campolongo P., Manieri R.A., Scattoni M.L., Frau R., Trezza V., La Rana G., Russo R., Malignano A., Gessa G.L., Cuomo V., and Piomelli D. Anxiolytic-Like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology (2006) 10.1038/sj.npp.1301061
7. Braida D., and Sala M. Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats. Neuroreport 11 (2000) 2025-2029
8. 9-Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur. J. Pharmacol. 506 (2004) 63-69
9. Calignano A., La Rana G., Beltramo M., Makriyannis A., and Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur. J. Pharmacol. 337 (1997) R1-R2
10. Chhatwal J.P., Davis M., Maguschak K.A., and Ressler K.J. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30 (2005) 516-524
11. 1A antagonist, WAY-100635. Psychopharmacology 132 (1997) 35-43
12. Dawson G.R., and Tricklebank M.D. Use of the elevated plus-maze in the search of anxiolytic agents. TIPS 16 (1995) 33-36
13. 1 receptors modulates anxiety in the shock-probe burying test. Eur. J. Neurosci. 20 (2006) 1059-1064
14. Devlin M.G., and Christopoulos A. Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. J. Neurochem. 80 (2002) 1095-1102
15. 1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. Eur. Neuropsychopharmacol. 14 (2004) 487-495
16. 3 receptors in rat nodose ganglion neurons. J. Neurophysiol. 73 (1995) 907-910
17. Fernandez-Espejo E., and Galan-Rodriguez B. Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor. Psychopharmacology 175 (2004) 220-224
18. Gaetani S., Cuomo V., and Piomelli D. Anandamide hydrolysis: a new target for anti-anxiety drugs?. Trends Mol. Med. 9 (2003) 474-478
19. Giuffrida A., Rodriguez de Fonseca F.R., Nava F., Loubet-Lescoulie P., and Piomelli D. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur. J. Pharmacol. 408 (2000) 161-168
20. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., Tontini A., Tarzia G., Mor M., Trezza V., Goldberg S.R., Cuomo V., and Piomelli D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. 102 (2005) 18620-18625
21. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. 65 (1995) 319-395
22. Griebel G., Rodgers R.J., Perrault G., and Sanger D.J. Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacol. Biochem. Behav. 57 (1997) 817-827
23. 1A receptor antagonists. Psychopharmacology 144 (1999) 121-130
24. 1A receptor antagonists in three rat models of anxiety. Neuropharmacology 39 (2000) 1848-1857
25. 1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57 (2005) 261-267
26. 1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 16 (2002) 1395-1398
27. Haller J., Varga B., Ledent C., and Freund T.F. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav. Pharmacol. 15 (2004) 299-304
28. Handley S.L. SL5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol. Ther. 66 (1995) 103-148
29. Hermann H., Marsicano G., and Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109 (2002) 451-460
30. Hill M.N., and Gorzalka B.B. Pharmacological enhancement of cannabinoid CB(1) receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur. Neuropsychopharmacol. 15 (2005) 593-599
31. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54 (1996) 21-30
32. Holmes A. Targeted gene mutation approaches to the study of anxiety-like behavior in mice. Neurosci. Biobehav. Rev. 25 (2001) 261-273
33. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., and Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9 (2003) 76-81
34. Kelley B.G., and Thayer S.A. Delta 9-tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in culture. Neuropharmacology 46 (2004) 709-715
35. Kimura T., Ohta T., Watanabe K., Yoshimura H., and Yamamoto I. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol. Pharm. Bull. 21 (1998) 224-226
36. Malone D.T., and Taylor D.A. Modulation of delta9-tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat. Br. J. Pharmacol. 124 (1998) 1419-1424
37. 1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav. Pharmacol. 15 (2004) 21-27
38. Mari{dotless}n S., Marco E., Biscaia M., Fernandez B., Rubio M., and Guaza C. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol. Biochem. Behav. 74 (2003) 649-656
39. 1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159 (2002) 379-387
40. Mendelson W.B., and Basile A.S. The hypnotic actions of the fatty acid amide, oleamide. Neuropsychopharmacology 25 (2001) S36-S39
41. Molina-Holgado F., Alvarez F.J., Gonzalez I., Antonio M.T., and Leret M.L. Maternal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) alters indolamine levels and turnover in adult male and female rat brain regions. Brain Res. Bull. 43 (1997) 173-178
42. 1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 20 (1997) 491-496
43. Onaivi E.S., Green M.R., and Martin B.R. Pharmacological characterization of cannabinoids in the elevated plus maze. J. Pharmacol. Exp. Ther. 253 (1990) 1002-1009
44. Patel S., and Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J. Pharmacol. Exp. Ther. 318 (2006) 304-311
45. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., and Hillard C.J. Endocannabinoid signalling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145 (2004) 5431-5438
46. Pellow S., Chopin P., File S.E., and Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14 (1985) 149-167
47. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4 (2003) 873-884
48. Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xie X.Q., and Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. 96 (1999) 5802-5807
49. Rodriguez de Fonseca F., Rubio P., Menzaghi F., Merlo-Pich E., Rivier J., Koob G.F., and Navarro M. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37] CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 276 (1996) 56-64
50. Rodriguez de Fonseca F., Del Arco I., Bermudez-Silva F.J., Bilbao A., Cippitelli A., and Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 40 (2005) 2-14
51. Rowland N.E., Mukherjee M., and Robertson K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology 159 (2001) 111-116
52. 1A receptors. Neurochem. Res. 30 (2005) 1037-1043
53. Rutkowska M., Jamontt J., and Gliniak H. Effects of cannabinoids on the anxiety-like response in mice. Pharmacol. Rep. 58 (2006) 200-206
54. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., and Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129 (2000) 227-230
55. Straiker A., and Mackie K. Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J. Physiol. 569 (2005) 501-517
56. Valjent E., Mitchell J.M., Besson M.J., Caboche J., and Maldonado R. Behavioural and biochemical evidence for interactions between Δ9-tetrahydrocannabinol and nicotine. Br. J. Pharmacol. 135 (2002) 564-578
57. Viveros M.P., Marco E.M., and File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol. Biochem. Behav. 81 (2005) 331-342
58. 1 receptors in mood and anxiety disorders. Behav. Pharmacol. 16 (2005) 315-331
59. Zygmunt P.M., Chuang H., Movahed P., Julius D., and Hogestatt E.D. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur. J. Pharmacol. 396 (2000) 39-42